Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Controlled Clinical Trial
. 2009 Feb;35(1):38-46.
doi: 10.1007/s12020-008-9126-2. Epub 2008 Dec 3.

Myotoxic reactions to lipid-lowering therapy are associated with altered oxidation of fatty acids

Paul S Phillips  1 , Theodore P Ciaraldi, Dong-Lim Kim, M Anthony Verity, Tanya Wolfson, Robert R Henry; Scripps Mercy Clinical Research Center
Collaborators, Affiliations
Controlled Clinical Trial

Myotoxic reactions to lipid-lowering therapy are associated with altered oxidation of fatty acids

Paul S Phillips et al. Endocrine. 2009 Feb.

Abstract

Despite exceptional efficacy and safety, fear of muscle toxicity remains a major reason statins are underutilized. Evidence suggests that statin muscle toxicity may be mediated by abnormalities in lipid metabolism. To test the hypothesis that myotubes from patients intolerant of lipid-lowering therapies have abnormal fatty acid oxidation (FAO) responses we compared muscle from 11 subjects with statin intolerance (Intolerant) with muscle from seven statin-naive volunteers undergoing knee arthroplasty (Comparator). Gross muscle pathology was graded and skeletal muscle cell cultures were produced from each subject. FAO was assessed following treatment with increasing statin concentrations. There was no difference in muscle biopsy myopathy scores between the groups. Basal octanoate oxidation was greater in Intolerant than in Comparator subjects (P = 0.03). Lovastatin-stimulated palmitate oxidation tended to be greater for Intolerant compared to Control subjects' myotubes (P = 0.07 for 5 microM and P = 0.06 for 20 microM lovastatin). In conclusion abnormalities in FAO of Intolerant subjects appear to be an intrinsic characteristic of these subjects that can be measured in their cultured myotubes.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Am J Physiol Endocrinol Metab. 2005 Jul;289(1):E151-9 - PubMed
    1. Diabetes. 1995 Aug;44(8):936-46 - PubMed
    1. Anal Biochem. 1976 May 7;72:248-54 - PubMed
    1. J Clin Invest. 2007 Dec;117(12):3940-51 - PubMed
    1. Diabetes Care. 2001 Aug;24(8):1335-41 - PubMed

Publication types

LinkOut - more resources